SMS Pharmaceuticals Ltd

- SMS Pharmaceuticals expects around 20% revenue growth and 20% EBITDA margin for FY '26. - Revenues anticipated to benefit from backward integration, product mix optimization, economies of scale, and price stabilization in key APIs. - New capex of INR 280 crores, completing by November 2026, aims to expand capacities, with revenues expected from FY '28 onward. - R&D investments and new product pipelines (including peptides from FY '29) support long-term earnings growth. - EBITDA margins improved to 20% in Q2 FY'26 (up 54% YoY), and PAT margins improved to 10% (up 80% YoY). - Backward integration projects contribute significantly to margin expansion and consistent cost control. - Strong order visibility in ARV and diversification across therapeutic categories enhance stable earnings outlook. - Net Asset Turnover is a strong 1.5x, indicating efficient capital utilization supporting profit growth.

The transcript from SMS Pharmaceuticals Limited's Q2 & H1 FY26 Earnings Conference Call dated November 11, 2025 does not explicitly provide detailed figures or specific information regarding the current or expected order book or pending orders. However, key related points include: - Strong visibility on ARV (antiretroviral) orders for the next 3 quarters due to multiple awarded tenders. - The company mentions continued momentum and confidence in achieving FY26 growth targets, implying a healthy order pipeline. - Backward integration and increased capacities suggest preparedness to handle growing orders. - Customer concentration is diversified, with the largest therapeutic category at 24% revenue, indicating a spread-out order base. No direct quantitative data on the current or expected order book or pending orders is disclosed in the transcript.

- There is no mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company is focusing on a capex plan of INR 280 crores for expansion, to be completed by November 2026, with anticipated revenues from FY 2028. - They have already invested close to INR 150 crores in backward integration projects over the past 12 to 18 months. - No discussion on raising fresh capital via equity or debt was made during the Q&A or the management commentary. - The company appears to be funding expansions and R&D internally or through existing resources without new fundraising indicated.

- SMS Pharmaceuticals has an ongoing capex program of INR 280 crores, slated for completion by November 2026. - The capex aims to expand capacities for existing APIs and build capacities for new product pipelines. - Included in the capex is an INR 30 crores outlay for land acquisition for a greenfield project. - Investments have begun in R&D for peptide initiatives, targeting commercial operations to start in FY 2029. - The project is expected to generate revenue starting FY 2028. - Approximately INR 150 crores invested over the last 12-18 months in backward integration to build in-house intermediate capabilities, enhancing cost, supply chain, and quality control.

- SMS Pharmaceuticals expects around 20% growth in revenue for FY '26, supported by strong demand and market share gains across key APIs. - Revenue from operations for H1 FY '26 grew 21% year-on-year to INR 438.4 crores. - The company aims to scale Ibuprofen API production to 5,000 tons in FY '26, targeting around 450 tons per month. - Backward integration and capacity expansions are expected to further improve gross margins and profitability in coming quarters. - New capex of INR 280 crores is underway, targeting completion by November 2026, with anticipated revenue contributions from FY '28. - Strong visibility on ARV segment growth is expected for the next three quarters due to tender awards. - The company plans to diversify and expand products, including peptide initiatives, with commercial operations targeted in FY '29. - Overall, growth will be driven by backward integration benefits, R&D advancements, and expanded capacities.